Abstract: This study investigated the effect of various treatments with TGF-β1 in osteogenic differentiation of human periodontal ligament (HPDL) cells.
Introduction
The periodontal ligament (PDL) is a connective tissue consisting of heterogeneous population which includes undifferentiated mesenchymal cells, osteoprogenitors, and fibroblasts. Cells in PDL exhibit the potential to differentiate into osteoblasts in vitro. 1) A recent study reported that human PDL contains stem cells and consequently PDL stem cells have the potential to generate cementum/PDL-like tissue. 2, 3) Therefore, PDL is featured as a useful source of regenerative therapy.
Transforming growth factor-β1 (TGF-β1) plays a pivotal role in connective tissue regeneration and bone remodeling. Previous reports demonstrated that TGF-β1 has significant effects in osteogenic differentiation and bone formation. [4] [5] [6] [7] [8] TGF-β1 increased mRNA levels of osteoblastic differentiation markers and alkaline phosphatase (ALP) activity in murine bone marrow stromal cells. 6) TGF-β1 was rapidly and transiently increased in orthodontic tooth movement and was associated with bone remodeling in vivo. 9) On the other hand, TGF-β1 blocked osteogenesis by a variety of mechanisms depending on cell density, TGF-β1 concentration and differentiation stage of the cells. [10] [11] [12] TGF-β1 also blocked odontogenesis by downregulation of dentin sialophosphoprotein. 13) The mitogen-activated protein kinase (MAPK) pathway has been proposed to negatively regulate Smad pathway and osteoblast mineralization. 14, 15) Some studies reported osteogenic differentiation. 10, 16, 17) These ambiguous results may be due to variation in the cell models used to analyze TGF-β1 function.
TGF-β family-induced Smad pathway involve two different classes of serine/threonine kinase receptors called types I and II. 18) TGF-β interact with heterotetrameric complexes of type I and II receptors, which lead to phosphorylation-dependent activation of the dormant type I receptor kinase, in turn, phosphorylated downstream substrates, called receptor-regulated Smads (RSmads). 19) Smad1, Smad5 and Smad8 are activated by BMPs and Smad2 and Smad3 are activated by TGF-β or activins. These RSmads, which formed hetero-oligomeric complexes with common Smad (Smad4), translocate to the nucleus where they function as transcription factors via direct DNA binding. 20) Inhibitory Smads (I-Smad), including Smad6 and Smad7, act as inhibitors of TGF-β family signaling pathway. 21, 22) In addition, non-Smad pathways directly or indirectly modify Smad phosphorylation and regulate TGF-β function. 23) Although these reports suggested that TGF-β/Smad pathway could be the major player for induction of osteogenesis, they did not fully explain either the dual effect of TGF-β signaling or the mechanism by which TGF-β1 influences osteogenesis. To better understand the signaling pathways mediating TGF-β1 in PDL cells, we examined the activation of Smad pathway and the role of TGF-β1 in osteoblastic differentiation of human PDL (HPDL) cells.
Materials and Methods

Cell culture and osteogenic differentiation
Normal HPDL cells, defined as pan cytokeratin negative, were purchased from Lonza (Basel, Switzerland) and cultured in In the process of multiple treatments with TGF-β1, OBM containing fresh TGF-β1 was changed every 12 h.
Assay of alkaline phosphatase (ALP) activity
For ALP staining, the cells were fixed in 4% paraformaldehyde for 5 min at room temperature. 5'-tcattttggtgattgcttcct-3'
5'-gcccaatacgaccaaatcc-3' 
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cultured cells using QIAzol reagent (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. cDNA was synthesized using highcapacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). qRT-PCR analysis was performed using Premix Ex Taq TM reagent (Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. The target genes were RUNX2, alkaline phosphatase (ALPL), bone sialoprotein (IBSP) and osteocalcin (BGLAP). GAPDH was used as an internal control.
All primers and probes of these target genes presented in Table 1 were designed using Probefinder v2.45 (http://qpcr.
probefinder.com/roche3.html).
Protein extraction and immunoblotting
The cells were lysed with lysis buffer (10 mM Tris-Hcl [pH 7
.5], 150 mM NaCl, complete protease inhibitor mixture, 1 mM antibodies were visualized using chemiluminescent substrate (ECL plus, GE Healthcare UK Ltd., Buckinghamshire) and exposed to Hyperfilm ECL (GE Healthcare).
Statistical analysis
Each experiment was repeated three times. When ANOVA indicated differences among the groups, multiple comparisons of each experimental group were performed using Bonferroni test.
Results
Characterization of HPDL cells and the effect of TGF-β1 in osteogenesis
OBM or OBM + Dex treatment significantly increased ALP activity in HPDL cells (Fig. 1A and 1C ). TGF-β1 was added to HPDL cells at different concentrations (0, 0.1, 1, 10, 50, and 100 ng/ml). Both the number of ALP positive cells and intensity of staining strongly increased in low dose TGF-β1 treatment (Fig.   1B ). ALP activity was strongly induced by 0.1 or 1 ng/ml TGF-β1, but weakly induced by 10 ng/ml or higher TGF-β1 compared to low dose TGF-β1 (Fig. 1C) . Runx2 mRNA expression was significantly increased by 1 ng/ml TGF-β1, but was strongly down regulated (to a level much lower than the control group) by 100 ng/ml TGF-β1 treatment (Fig. 1D) . Similar results were observed when mRNA expression of ALP or BSP was assayed ( Fig. 1E and   1F ). Thus, the effect of TGF-β1 in the expression of these osteogenic markers was inversely proportional to the concentration of TGF-β1.
Strong phosphorylation of Smad3 by a low dose of TGF-β1 promoted osteogenic differentiation of HPDL cells
Strong phosphorylation of Smad3 was detected following treatment of cells with 1 ng/ml TGF-β1 for 1 h. This phosphorylation was stronger than that observed for 100 ng/ml TGF-β1 ( Fig. 2A) . Smad3 mRNA expression was altered by TGF-β1 treatment over time (Fig. 2B) . 2C) or 96 h (Fig. 2D) after pretreatment with SB505124 for 1 h.
SB505124 dose-dependently decreased TGF-β1-induced ALP in
parallel with a decrease in pSmad3.
Multiple treatments with low dose TGF-β1 inhibited osteogenic differentiation
We then tested the effect of repeated treatment with 1 ng/ml TGF-β1 on HPDL-osteogenic differentiation. As expected, strong phosphorylation of Smad3 was detected after the first treatment with 1 ng/ml TGF-β1 for 1 h (Fig. 3B) . Neither the second nor the third treatments induced much phosphorylation of Smad3 ( Fig.   3B and data not shown, respectively). The first treatment with 1 ng/ml TGF-β1 strongly induced ALP but multiple treatments inhibited ALP expression (Fig. 3C) . Inhibition of TGF-β/ Smad pathway with SB505124 at every 12 h before TGF-β1 treatment failed to induce ALP expression (Fig. 3C) . Phosphorylated Smad3
was not detected in SB505124 treatment (Fig. 3D ).
Single treatment of low dose TGF-β1 induced RUNX2, ALPL,
IBSP and BGLAP expression
As shown in Fig. 4 , RUNX2 and ALPL expression began to increase after 24 h or 48 h with single 1 ng/ml TGF-β1 treatment.
The expression of these mRNAs showed little increase following a single 100 ng/ml TGF-β1 treatment or multiple treatments with 1 ng/ml TGF-β1. A single 1 ng/ml TGF-β1 treatment induced all osteogenic differentiation markers studied here while multiple or 100 ng/ml TGF-β1 treatment reduced them.
SMAD7 is transcriptionally induced by TGF-β and negatively regulated TGF-β/ Smad signaling pathway. 21) SMAD7 expression was transiently and strongly induced under all conditions of TGF-β1 treatment at 2 h, and decreased thereafter (Fig. 4E) . Following single 1 ng/ml TGF-β1 treatment, SMAD7 expression continuously decreased and had almost reached the baseline level after 48 h of treatment. However, following 100 ng/ml or multiple TGF-β1 treatments, SMAD7 expression was maintained at higher levels relative to those following a single 1 ng/ml TGF-β1 treatment at 24 h and 48 h. The sustained high expression level of SMAD7 may be at least one of the reasons for the observed downregulation of pSmad3 by TGF-β1 treatments because SMAD7 inhibits TGF-β-receptor-induced Smad3 phosphorylation.
Discussion
In this paper we have shown that TGF-β1 both positively and negatively regulated osteogenic differentiation of HPDL cells and Smad3 phosphorylation depending on the concentration of TGF-β1 and its time of administration. HPDL cells used in our study were defined as pan cytokeratin negative cells. Thus they could be heterogenous containing population of mesenchymal cells, osteoprogenitors, and fibroblasts. 24 ) Indeed, we found that HPDL cells expressed RUNX2 at slightly higher levels than normal human dermal fibroblasts (data not shown), and we could barely detect ALP activity in these cells (Fig. 1A) . Osteoblast differentiation markers were significantly induced when cultured in OBM. Thus, HPDL cells are capable of differentiating into osteoblasts.
A single low dose of TGF-β1 treatment promoted osteogenic differentiation whereas treatment with repetitive low doses, or a single high dose, of TGF-β1 had much weaker effects in osteogenic differentiation. Zimmermann et al. reported that serum levels of TGF-β1 were significantly higher in bone fracture patients than in normal controls and that lower serum levels of TGF-β1 were related to delayed healing of fracture. 25) Several other reports also described the key role of TGF-β1 in matrix production, osteoblast precursor cell recruitment during bone repair and acceleration of bone formation. 4, [25] [26] [27] [28] However, in vitro studies showed that TGF-β1 could positively and negatively regulate osteoblast differentiation depending on the duration of TGF-β1 treatment or the differentiation stage of the cells. 7, 11, 15, 29) Thus, the exact mechanism by which TGF-β1 modulates osteoblast differentiation is unclear.
It was inferred from the results that TGF-β1 might initiate that mice with a targeted deletion of Smad3 were osteopenic, had decreased bone mineral density and a decreased rate of bone formation. 31) Together with our data (Fig. 2C and 2D ), these results suggest that TGF-β/Smad pathway (canonical pathway) plays an important role in osteogenic differentiation of HPDL cells. Smad phosphorylation decreased after second treatment with 1 ng/ml TGF-β1 (Fig. 3B) . Multiple treatments of TGF-β1 abolished the upregulation of ALP and osteogenic differentiation marker genes ( Fig. 3C and 4 ). As shown in Fig. 3A , first, we treated the cells with 1 ng/ml TGF-β1 alone and then at 12 h later, these cells were treated with TGF-β1 with/without ALK5 inhibitor SB505124. We found that osteogenic differentiation was completely abolished regardless of SB505124 treatments (Fig. 3C [b] and [c]). Smad3 phosphorylation was completely inhibited by SB505124 treatment (Fig. 3D) . These results indicate that although Smad pathway was not active, the inhibition of osteogenic differentiation occurred by multiple treatments. Thus, we suggest that the inhibition of osteogenic differentiation is associated with non-Smad pathway.
We hypothesized that there may be a pathway which inhibits Smad3 phosphorylation that is only activated by a high dose or repetitive TGF-β1 treatment. This notion is supported by a previous report that Smad3 overexpression greatly enhanced ALP activity that was inhibited by TGF-β1 treatment. 30) Several other studies have reported that TGF-β1 inhibited osteoblastic differentiation via a non-canonical pathway such as ERK1/2 or JNK pathway. 14, 15, 32) Complex effects of TGF-β1 on cell function have been widely reported and have been termed "dual effect" of TGF-β1. 23, 29, 33, 34) Non-canonical pathways may play an important role in this dual effect of TGF-β signaling. We hypothesize that TGF-β1 may have a dual effect in osteogenesis which is either controlling positively or negatively via canonical and noncanonical pathways respectively. Since these non-canonical pathways and their regulation are very complex, further detailed studies are required to fully understand the regulation of osteogenesis by TGF-β signaling.
In conclusion, a low dose of TGF-β1 induced Smad3 phosphorylation and enhanced the expression of osteogenic differentiation markers. However, repetitive or high dose TGF-β1 treatment inhibited Smad3 phosphorylation and enhanced the expression of osteogenic differentiation markers. Smad3
phosphorylation plays an important role in osteogenesis whereas the non-canonical pathway may have an inhibitory function. These studies confirmed that TGF-β1 has a dual effect in osteogenesis and further studies of this dual effect will contribute to a better understanding of the pathological mechanism of periodontitis that will lead to new therapies.
